Kopran Ltd logo

Kopran Ltd

NSE : KOPRAN
BSE: 524280
SECTOR : PHARMACEUTICALS
No data to show from BSE
52w high/low icon
52w high/low
₹370.45 / ₹99.5
P/E ratio icon
P/E ratio
28.58
Dividend icon
Dividend
1.46
ROE icon
ROE
8.37
ROCE icon
ROCE
11.2
Face value icon
Face value
10
Book value icon
Book value
₹85.88Cr
Market capital icon
Market capital
₹991.53Cr

Shareholding pattern

What is shareholding pattern? Who are shareholders?

Shareholding pattern represents the percentage of share ownership that different investors are holding in the company. A company can have multiple investors who invest in its shares. These are called as shareholders and there are two major categories of shareholders - promoters and public shareholders.
Promoters are typically the founders and public shareholders could be financial institutes like banks, insurance companies, domestic institutional investors, foreign institutional investors and common public.

Cash flow

What is a cash flow statement?

It is a financial statement that offers aggregate statistics on all cash inflows a business collects from its continuing activities and external sources of investment. It also includes all cash outflows over a specified time paying for company operations and investments.The main components of the CFS are cash from three areas: operating, investing, and financing activities...Read more

Balance Sheet

What is a balance sheet?

A balance sheet is a financial statement that records the assets, liabilities, and equity of a company at a certain point in time and provides a basis for estimating return rates and determining the capital structure. It offers a snapshot of what an entity owns and owes, as well as the sum that shareholders spend.The balance sheet complies with the following accounting equation in which assets on the one side, and liabilities plus shareholders' equity on the other, balance out:
Assets = Liabilities + Shareholder's Equity
This is used to conduct fundamental analysis or the estimation of financial ratios alongside other essential financial statements, such as income statement and statement of cash flows...Read more

Profit and loss

What is a profit and loss statement?

A profit and loss statement is a financial statement that represents the revenues, costs and expenses that the company has incurred during a quater or a fiscal year. It is also sometimes referred to as statement of profit and loss, income statement or statement of operations. This statement basically shows the investors and management whether the company has incurred profits or losses and in which areas.

Key Ratios

PE TTM
28.58
P/B
2.39
ROE
8.37
ROCE
11.2
Dividend yield
1.46%
EPS TTM
7.19
EBTIDA Growth
21.91
D/E
0.08
Sector PE
47.31
BV
₹85.88Cr

Peer Comparison

Dividends

What are dividends?

Dividend, in financial terms, means a certain amount shared with shareholders of a company or a mutual fund on a regular basis – monthly, quarterly or annually. Read more

Bonuses

What are bonuses?

A bonus issue is an offer given to the existing shareholders of the company to subscribe for additional shares. Instead of increasing the dividend payout, the companies off... Read more

Company News

Sorry, we do not have any data here.

Sector News

Sorry, we do not have any data here.
Kopran Ltd logo

About Kopran Ltd

Kopran was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov. '92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

Key info

Address
Parijat House 1076, Dr E Moses Road Worli, Mumbai, Maharashtra, 400018
Fax Nos.
91-22-24950363
Telephone Nos.
91-22-43661111
Email
investors@kopran.com
fbtwitterlinkedingithubinstagramyoutube